COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Bovine Intestinal Alkaline Phosphatase (bIAP) Modulating Rheumatoid Arthritis (ALS-003-2008)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01416493
Recruitment Status : Completed
First Posted : August 15, 2011
Last Update Posted : March 10, 2015
Aix Scientifics
Information provided by (Responsible Party):
Alloksys Life Sciences B.V.

Brief Summary:
This is a proof of concept study asking if alkaline phosphatase injections can reduce acute inflammation in rheumatoid arthritis patients.

Condition or disease Intervention/treatment Phase
Acute Rheumatoid Arthritis Drug: s.c. injections of bovine intestinal Alkaline Phosphatase Phase 1 Phase 2

Detailed Description:
This is a proof of concept study to establish the safety of subcutaneous (sc) treatment and the efficacy of alkaline phosphatase (AP) in reducing specific pro-inflammatory cytokines during and after 3 days of twice daily s.c. treatment. A total dose of 12000 Units AP will be administered by 2000 IU s.c. injection twice daily for 3 days. Subjects will be closely followed for 8 days and regular clinical observations will be made during 3 months. Close out will be 3 months after initiation of treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An OPEN LABEL Phase II Safety Study of Bovine Intestinal Alkaline Phosphatase (bIAP), an Inflammation Modulating Moiety, in RA Patients
Study Start Date : May 2011
Actual Primary Completion Date : April 2013
Actual Study Completion Date : April 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: bIAP treatment Drug: s.c. injections of bovine intestinal Alkaline Phosphatase
daily subcutaneous treatment with two injections of 2000IU bIAP for three days

Primary Outcome Measures :
  1. blood level of the pro-inflammatory cytokines: TNFα and IL6 [ Time Frame: 3 months ]
    The anticipated effects of bIAP will be short lived, within 4 days. However, in order to capture durable clinical responses or any late adverse effects, patients will be followed through 3 months at weeks 2, 4, 8 and 12 incorporating trial observations with routine monthly care to reduce disruption to patients.

Secondary Outcome Measures :
  1. RA clinical status expressed as Daily Activity Score (DAS-28) [ Time Frame: 3 months ]
    van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990 Nov;49(11):916-920

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

1. Male or non-pregnant, non-lactating female patients of any race with an age >18 years. Woman of child-bearing potential must be on regular contraceptives throughout the trial (Pregnancy tests).

1A: RA according to the 1987 revised ARA criteria (Arnett 1987) with an active disease with DAS28>3.2 despite the prior or concurrent use of DMARDs.

2. Patients may be on no active therapy or may be on continuous DMARD therapy including Methotrexate, Sulphasalazine, Leflunomide, Hydroxychloroquine, Myocrisin alone or in combination, or on NSAID treatment, or on steroid (prednisolone not more than 10mg/day).

3. Patients must have a measurable acute phase response: CRP (> 10mg/dl), ESR > 25. (to be measured on routine lab range CRP/ ESR/AP/ standard biochemistry)

4. Patients eligible for treatment with biological TNFα blockers and who are awaiting the administration of such treatment may enroll in the laboratory and safety protocols Data for Clinical Phase observations will be collected but will be handled as last observation carried forward for the final records prior to the administration of TNF blocking agent, should that occur within the 3-month Clinical Phase. The administration of TNFα blockers will not be delayed for the protocol.

5. Patients who have given written informed consent prior to participation in the trial and who undertake to comply with the protocol.

Exclusion Criteria:

  1. Patients who are unwilling or unable to be fully evaluated for follow-up.
  2. Patients who have an active infection or who are suspected of having systemic infection and or patients that are treated with antibiotics.
  3. Patients whose screening blood do not reflect a sufficient cytokine or acute phase response.
  4. Patients who have evidence of significant hepatic disease, including history of clinical signs or laboratory values of total bilirubin > 34.2 umol/L (> 2.0 mg/dL), ALT (>120) or AST (>135) corresponding to > 3X upper limit of normal.
  5. Alkaline phosphatase levels must be less 145 IU/L (routine clinical method)
  6. Patients who received investigational drugs in the 30 days prior to study drug administration, or are currently participating in a study during which the administration of investigational drugs within one month is anticipated.
  7. Patients who have renal insufficiency (history of creatinine >177umol/L or >2.0 mg/dL) or chronic renal failure requiring dialysis.
  8. Patients with severe neurological deficits (see Appendix I).
  9. Patients who have a recent history of drug substance or alcohol abuse.
  10. Patients with a diagnosis of idiopathic thrombocytopenia.
  11. Patients with a history of cancer who have received chemotherapy or radiation therapy within the past 3 months. Patients receiving only adjuvant hormonal therapy are not excluded. If the cancer has not resolved completely, the patient should not be enrolled without permission of Alloksys.
  12. Patients receiving oral glucocorticoids >10mg /day or any IV, IM or Intra articular dosing within 30 days of commencing the protocol.
  13. Patients who are vegetarians or veganists or those patients that may be expected not to be tolerant to bovine proteins, or not to wish exposure to bovine proteins for personal reasons.
  14. Patients who are, in the opinion of the Investigator or the Sponsor, unsuitable for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01416493

Layout table for location information
United Kingdom
Maidstone Hospital, Dept. Rheumatology
Maidstone, Kent, United Kingdom, ME16 9QQ
Sponsors and Collaborators
Alloksys Life Sciences B.V.
Aix Scientifics
Layout table for investigator information
Principal Investigator: Anthony Hammond, MD Maidstone Hospital, Dept. Rheumatology
Additional Information:
Layout table for additonal information
Responsible Party: Alloksys Life Sciences B.V. Identifier: NCT01416493    
Other Study ID Numbers: REUMAP
2008-007346-63 ( EudraCT Number )
First Posted: August 15, 2011    Key Record Dates
Last Update Posted: March 10, 2015
Last Verified: March 2015
Keywords provided by Alloksys Life Sciences B.V.:
acute rheumatoid arthritis
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases